From a Twinkle in the Eye to a Blockbuster Drug

By Needleman, Philip | Research-Technology Management, November/December 2001 | Go to article overview

From a Twinkle in the Eye to a Blockbuster Drug


Needleman, Philip, Research-Technology Management


THE IRI MEDALISTS ADDRESS

The story of Celebrex(R) holds lessons for R&D leaders everywhere.

OVERVIEW: Drug discovery and development remains an arduous and risky enterprise, despite the unprecedented power of genomics and other tools. The story behind Celebrex(R0 (celecoxib), a highly successful medicine for arthritis, illustrates the importance of key management practices in the R&D process. A successful head of R&D must (1) select excellent targets for drug discovery, (2) drive rapidly to "killer" experiments that provide decision-critical information, (3) focus limited resources to enhance speed, (4) break down barriers between research and manufacturing, and (5) manage product life cycles effectively.

Modern drug discovery is a difficult, arduous process, filled with enormous risk. Success, however, can provide relief of human suffering and increased longevity, worthy goals by any standard. Because the discovery and development of new pharmaceuticals is so difficult, application of the best management techniques to the process is essential. The story behind Celebrex(R) (celecoxib), a highly successful pain reliever and antiinflammatory medicine used in the treatment of arthritis, illustrates many of these management tools and principles very well.

For more than 100 years, salicylates have been used to relieve pain and inflammation. Unfortunately, the naturally occurring compound, salicylic acid, has severe gastrointestinal and other side effects. Over 100 years ago, a Bayer chemist synthesized the acetylated derivative of salicylate, to obtain a compound, aspirin, with fewer side effects. Seventy-five years after the synthesis of aspirin, John Vane showed that the drug acted by decreasing the synthesis of inflammation-promoting prostaglandins, which are produced in the body through the action of an enzyme called cyclooxygenase. In time, a whole class of pharmaceuticals called non-steroidal anti-inflammatory drugs (NSAIDs) was developed, including ibuprofen and naproxen. These acted mechanistically like aspirin but had improved pharmacological profiles with fewer side effects. By the mid-1980s, there were at least 22 NSAIDs being sold on the global pharmaceutical market.

While traditional NSAIDs were certainly an improvement over high-dose aspirin therapy for the treatment of arthritis, they still retained some serious side-effects. Because prostaglandins are involved in the protection of the gastrointestinal tract from hydrochloric acid and are also involved in blood clotting, NSAID's tend to cause gastrointestinal bleeding as a severe side effect. In fact, in the United States alone in 1998, there were at least 120,000 hospitalizations per year resulting from NSAID-induced complications, and perhaps more than 16,000 deaths.

It was against this historical backdrop that in the mid1970s my colleagues and I at Washington University in St. Louis became interested in the biology of inflammation. The experimental system that we chose to study was perfused rabbit kidney, which, as a model for inflammation, had the great advantage of having a built-in contralateral control (the kidney on the opposite side). It turned out that inflamed kidney produced large quantities of prostaglandin-like substance, which was reduced to zero by the concomitant application of aspirin. Follow-up work over the course of several years led to the hypothesis in 1988 that there were really two forms of cyclooxygenase in the body. One form, dubbed COX-1, was apparently a "house-keeping" or constitutive enzyme, found in many tissue types and responsible for the steady synthesis of those prostaglandins involved in the protection of the gastrointestinal tract and in blood clotting. The other form of the enzyme, imaginatively named COX-2, appeared to be inducible, that is, its level was dramatically increased at sites of inflammation.

In 1989, I joined the Monsanto Company to become chief scientist and later head of R&D of Monsanto's pharmaceutical subsidiary, Searle. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

From a Twinkle in the Eye to a Blockbuster Drug
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.